Age-Based Screening May Be Screening Out the Wrong Patients
For years, the pathway to germline genetic testing in oncology has run through a single practical question: how old was the patient when cancer was diagnosed? Most testing is offered to people diagnosed before age 50, built on the assumption that early-onset disease is more likely to stem from an inherited pathogenic variant than cancer that emerges later in life. A study published in Cancer Discovery and led by researchers at Memorial Sloan Kettering Cancer Center argues that this heuristic may be excluding a large share of the patients who actually carry inherited risk.
The stakes are not abstract. Germline pathogenic variants — inherited alterations in genes implicated in cancer — can signal elevated risk for the person who carries them, open the door to screening for relatives who may share that risk, and in some cases help inform treatment choices. When testing is rationed by age, those downstream benefits are rationed along with it.
“The current standard practice is, in many ways, a gatekeeper for genetic testing,” said Zsofia K. Stadler, M.D., clinical director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center and a co-corresponding author of the study. She and her colleagues set out to quantify how much inherited cancer risk is lost when age at diagnosis drives the decision. Their hypothesis was that universal germline testing would surface clinically meaningful findings across the age spectrum and could prompt more testing among family members who might also carry hereditary risk.
Inside the Study Design
To test that idea, the research team did what routine care rarely does: they performed germline genetic testing on every patient with a solid tumor at their institution, regardless of age. The cohort totaled 39,184 individuals — a scale large enough to make the comparison between age-gated and universal strategies meaningful rather than anecdotal.
Testing relied on the MSK-Integrated Mutation Profiling of Actionable Targets (MSK-IMPACT) assay, which in this study evaluated 94 germline pathogenic variants using DNA isolated from patients’ blood or saliva. By removing age from the eligibility equation entirely, the investigators created a dataset capable of showing precisely what a purely age-based strategy would overlook.
That design choice matters. Studies that test only younger patients can describe the genetics of early-onset disease, but they cannot count the carriers who sit on the other side of the cutoff. A universal testing cohort can, and that is what makes this analysis unusually direct in its challenge to conventional practice.
What the Numbers Showed
Across the full cohort, 16.3% of patients harbored at least one of the germline pathogenic variants included in the assay — roughly one in six people tested.
The headline finding, however, concerns what would have happened under business-as-usual. Had the researchers limited testing to patients under age 50 — the typical cutoff for germline sequencing — they would have missed the majority of inherited gene variants detected in the study. The conventional threshold, in other words, does not function as a gentle filter. It functions as a net with very large holes.
That result reframes a familiar trade-off. Age-based testing is often defended as a way to concentrate limited genetic counseling and sequencing capacity where pretest probability is believed to be highest. The data here suggest that inherited risk among older patients is common enough to matter at population scale, and that whatever efficiency the cutoff delivers is purchased with a substantial number of missed diagnoses.
Why the Age Threshold Persisted
The logic behind restricting testing was never unreasonable on its face. If inherited variants skew toward earlier cancer onset, then testing younger patients should yield more positive results per test performed. But population-level yield and individual-level usefulness are different questions. A strategy can be statistically efficient in the aggregate and still leave most carriers unidentified, particularly when the conditions involved are common enough that even a modest prevalence among older patients translates into large absolute numbers.
Stadler’s framing is pointed. Rather than treating age 50 as a fixed rule, her team asked what universal testing would actually reveal. In their cohort, the answer was a considerable reservoir of inherited risk that age alone would have concealed.
Consequences for Families and for Treatment
The clinical consequences of a missed germline finding extend well beyond the patient in the examination room. Identifying a pathogenic variant allows clinicians to flag cancer risk in a patient’s family members, who may then pursue their own testing and preventive care. A missed result can therefore mean a missed opportunity for an entire household or extended family — a cascade of screening and surveillance that never begins.
There is also a therapeutic dimension. According to the research, the presence of certain germline pathogenic variants can potentially guide patients’ treatments, which means a missed variant may not only affect risk assessment but also narrow the information available when therapy decisions are made.
What Universal Testing Would Require
Accepting the study’s implication — that age should not be the primary gate on germline screening — raises practical questions that no single cohort study can settle on its own. Broadening eligibility would increase demand for genetic counseling, expand the volume of sequencing and variant interpretation, and generate more results of uncertain significance that require careful follow-up. Health systems would need to decide how to absorb that workload without diluting the quality of care for the patients who need it most.
None of those obstacles is unique to germline testing, and none is a reason to keep a cutoff that demonstrably misses most carriers in a large, real-world population. But the path from evidence to practice runs through budgets, staffing, and reimbursement — the unglamorous machinery that determines whether a finding like this one changes what happens in a clinic.
Key Takeaways
- Investigators performed germline testing on all 39,184 patients with solid tumors at Memorial Sloan Kettering Cancer Center, with no age restriction.
- The MSK-IMPACT assay assessed 94 germline pathogenic variants using DNA from blood or saliva.
- Overall, 16.3% of patients carried at least one of the tested germline pathogenic variants.
- Restricting testing to patients under 50 would have missed the majority of inherited variants identified in the study.
- Identifying variants can help flag cancer risk in relatives and can potentially inform treatment decisions.
The Bottom Line
The study does not merely add detail to a known picture; it questions the premise on which a widespread testing rule rests. If a majority of inherited variants appear in patients who would never have been offered a test under the age-50 convention, then the convention is not a reasonable proxy for inherited risk. It is a structural blind spot.
What comes next will depend on whether health systems treat age at diagnosis as a starting point for conversation or as a hard boundary. The evidence assembled here points toward the former — and toward a future in which the decision to test is driven by what a patient and their family might gain from knowing, rather than by how old the patient happened to be on the day of diagnosis.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
